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Recombinant human Acid Alpha Glucosidase (GAA) is the therapeutic enzyme used for the
treatment of Pompe disease, a rare genetic disorder characterized by GAA deficiency in the
cell lysosomes (Raben et al., Curr Mol Med. 2002; 2:145–166). The manufacturing process
for GAA can be challenging, in part due to protease degradation. The overall goal of this
study was to understand the effects of GAA overexpression on cell lysosomal phenotype and
host cell protein (HCP) release, and any resultant consequences for protease levels and
ease of manufacture. To do this we first generated a human recombinant GAA producing
stable CHO cell line and designed the capture chromatographic step anion exchange (IEX).
We then collected images of cell lysosomes via transmission electron microscopy (TEM) and
compared the resulting data with that from a null CHO cell line. TEM imaging revealed
72% of all lysosomes in the GAA cell line were engorged indicating extensive cell stress; by
comparison only 8% of lysosomes in the null CHO had a similar phenotype. Furthermore,
comparison of the HCP profile among cell lines (GAA, mAb, and Null) capture eluates,
showed that while most HCPs released were common across them, some were unique to the
GAA producer, implying that cell stress caused by overexpression of GAA has a molecule
specific effect on HCP release. Protease analysis via zymograms showed an overall reduc-
tion in proteolytic activity after the capture step but also revealed the presence of co-eluting
proteases at approximately 80 KDa, which MS analysis putatively identified as dipeptidyl
peptidase 3 and prolyl endopeptidase. VC 2017 American Institute of Chemical Engineers
Biotechnol. Prog., 000:000–000, 2017
Keywords: proteomics, host cell protein, proteases, acid alpha glucosidase, Chinese hamster
ovary cells, biotherapeutic recombinant protein overexpression, downstream purification
Introduction
Host cell protein (HCP) release during the production of
therapeutic proteins is a critical quality attribute that must be
monitored and reduced to acceptable levels during the pro-
duction of a biotherapeutic protein.1 Being able to control
HCP release during harvest, and their removal via down-
stream processing, is thus an important component of the
manufacturing of such molecules and must be reported to
the regulatory authorities. Typical purity targets for a mono-
clonal antibody (mAb) are <100 ppm HCP, <10 ng/dose
DNA, and <5% product aggregates.2 Some HCPs are known
to be co-purified with the recombinant protein target, while
others, specifically proteases, are reported to lead to product
degradation.3 As a wide range of recombinant products are
negatively affected by the presence of proteases such as
reported for mAbs,4 fusion proteins,5 coagulation factors6
and based on personal communication with BioMarin who
have manufacturing experience of GAA therapeutic enzyme
products, we suspect GAA in certain conditions to also be
similarly potentially affected.
Expression of therapeutic proteins from mammalian cell
platforms presents multiple challenges associated with remov-
al of both product related and host cell derived (e.g., proteins,
DNA, RNA, lipids) impurities. It is believed that stress result-
ing from protein overexpression causes morphological changes
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to cell structure and an increase in HCP released, which can
impact on downstream processing. As widely described in the
literature, HCPs in final drug formulation can potentially have
an impact on drug toxicity and patient safety.7
In addition to target molecule overexpression, another fac-
tor that can have an impact on cell stress is the high local
energy dissipation rate associated with bubble bursting dur-
ing culture, particularly in stirred bioreactors. A recent
paper8 describes how cell death and lysis cause HCP release
in the broth throughout the duration of the culture and are
critical process parameters difficult to track as cell counters
cannot account for lysed cells. The cell viability, cell size
and choice of harvest day all therefore contribute to total
HCP released due to shear during primary recovery.9
Historically, immunoassay-based techniques such as ELISA
have been used as high throughput methods to quantify HCP
amounts during process development, manufacturing and in
final product formulations. This approach has been important
in the development of HCP assays and process development
and product characterization; however, there are some inher-
ent limitations with the use of ELISA. For example, the poly-
clonal antibodies used for detection are raised against the
spectrum of HCPs found in the host cell (or in some cases
mixed pools of cells), results are thus generally cumulative of
all the HCPs present in a sample and cannot provide identifi-
cation of single critical HCPs of interest, and only those
HCPs which are immunogenic can be detected. These issues
all potentially have impact as to whether all HCPs are being
measured and with sufficient sensitivity.1,10 The need to
simultaneously quantify and identify HCPs in samples with
greater sensitivity and precision, has resulted in the advance-
ment of orthogonal analytical techniques based on LC-MS/
MS. High throughput monitoring of HCPs via LC-MS/MS is
becoming ever more common.11,12
Here, we have specifically investigated the production of
the lysosomal enzyme GAA in CHO cells and the impact on
the HCP profile. To do this, rather than describing the full
bioprocess involved in GAA purification, we have focused
on HCPs present after the capture chromatographic step
(IEX) to compare among three mammalian cell lines: a
GAA, a mAb, and a null producer. The mAb producer was
used as an example of another cell line overexpressing a
recombinant protein to provide an alternate control to that of
a null cell line. As seen in Swanson et al.13 IEX is an
incredibly useful tool in clarifying complex mixtures of
HCP, although to achieve an acceptable level of purification
usually additional orthogonal techniques and depth filtra-
tion14 are used. In the case of GAA, the cysteine proteases
Cathepsin B and Z are believed to be responsible for target
molecule (GAA) degradation,15,16 and it is therefore impor-
tant to track their expression, release and removal throughout
the bioprocess. According to the work reported by Korn-
feld17 (Figure 1) as GAA enters the ER as a newly formed
polypeptide, it undergoes post-translational modifications in
the ER and Golgi before approximately 10-20% of enzyme
is secreted outside the cell while the rest ends up in lyso-
some where it resides. It is hypothesized that while all mam-
malian cells produce a basal amount of GAA, the amount in
recombinant overexpressing CHO cells will be much higher
and this will have an effect on the phenotype of the
Figure 1. GAA Pathway with permission from The FASEB journal.17
Text adapted from Refs. 18, 19, and 20, with permission.
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lysosome. In this work, we use high resolution label free
LC-MS/MS to compare HCPs of three different CHO cell
lines: a GAA producer, a mAb producer and a null. We also
assess cell stress deriving from enzyme overexpression by
comparing transmission electron microscopy (TEM) generat-
ed images of lysosomes, the organelles that store GAA.
Materials and Methods
Cell line generation
The site-specific gene integration expression system Flp-In/
FRT (cat# V601020 ThermoFisher) was used to generate sta-
ble CHO clonal lines carrying the human GAA expression
gene and HygromycinB resistance for selection. The GAA-
XL6 sequence (cat# SC125512 Origene) was cloned into the
pcDNA/FRT plasmid using standard cloning techniques and
the appropriate restriction enzymes (Not1 and Ase1), TSAP
and ligase enzymes. OneShot TOP10 chemically competent E.
coli cells (cat# V601020, ThermoFisher) were used for trans-
formation and amplification of the genetic material following
the manufacturer’s protocol. Single colonies were picked from
Petri dish and amplified overnight under vigorous shaking
(250 rpm, 378C) in LB ampicillin media. DNA was purified
with the commercially available Qiagen Miniprep Kit (Qiagen
Cat No.ID: 27104).
To ensure size and direction of insertion of the GAA gene
were correct, a series of agarose gels were run of restriction
digests and the plasmid was sequenced using custom primers
(data not shown) that confirmed the correct sequence was pre-
sent in the required orientation and in frame. The resulting
plasmid DNA construct was used to transiently transfect the
CHO Flp-In cell line (Thermo Fisher) using FreeStyleTM MAX
CHO Expression System (cat# K900020, Thermo Fisher). Fol-
lowing confirmation of the presence of GAA in transiently
transfected culture supernatant via western-blot analysis, stable
cell line generation was performed. A pcDNA/FRT-GAA con-
struct was used to transfect the CHO Flp-In (cat# R75807,
Thermo Fisher Scientific) commercially available cell line that
had been previously adapted to grow in chemical defined CD-
CHO media (ThermoFisher)1 8 mM glutamine, using PEI
(Polyethylenimine linear, cat#9002-98-6 Sigma Aldrich) as a
transfection agent and the pOG44 Flp-Recombinase Expression
Vector (cat# V600520 Thermo Fisher Scientific) in a (1:9):3
ratio (3 mg of plasmid DNA added to 27 mg of pOG44, incu-
bated 5 min at RT, followed by 90 mg of linear PEI). Colonies
that emerged under 250 mg/mL hygromycin B selection pres-
sure were subject to limiting dilution cloning (LDC). A total of
360 wells were plated of which only 6 ultimately grew, and
eventually only 3 were viable. The three final cell lines were
assessed for GAA titer and growth performance. Cell counting
and viability was monitored using a Beckman Coulter ViCell
while GAA titer was measured via Okumiya GAA diagnostic
assay method,21 using a GAA reference standard for activity
and concentration comparison.
Lysosomal imaging using TEM
Lysosome images were collected using a Joel 1010 TEM
with Orius Gatan camera system. Small aliquots (150 mL of
106 viable cell/mL) of null CHO and GAA CHO cells were
taken aseptically from culture shake flasks, immediately cen-
trifuged (2000 g, 5 min) and the supernatant removed. A
solution of 2% paraformaldehyde, 1.5% glutaraldehyde in
0.1 M cacodylate buffer pH 7.3 was added to the pellet and
incubated at 48C. After a series of washes (0.1 M cacodylate
5 min, H2O 5 min, 0.5% uranyl acetate 20 min, 0.1 M caco-
dylate 5 min, H2O 5 min) pellets were dehydrated via
increasing concentration ethanol washes and eventually fixed
onto epoxy resin (12 g agar, 8 g dodecenylsuccinic anhydride,
5 g methyl nadic anhydride, 0.65 mL N-benzyldimethylamine,
Sigma Aldrich) and hardened for 24 h at 608C. Ultrathin sli-
ces of 70 nm were prepared using a diamond knife on a
Reichetr ultracut E microtome and collected on a 200 mesh
copper grids. Finally, sections were stained with uranyl ace-
tate and lead citrate. In total 33 images of single cells per
sample were taken. Each image was analyzed for lysosome
number and condition. Lysosomes observed were classified in
three categories: Full (F) if the lysosome seemed to be
completely full with matter, Half Full (HF) if the internal
structure was partially filled or Empty (E) if the structure
appeared to be clear of any matter visually. The numbers
were collated in Excel and the following analysis conducted:
(1) Total number of lysosomes per cell; (2) Number of E, HF,
F counted per cell; (3) Standard Deviation over population;
(4) Standard Error over population.
Cell culture
A cell bank vial (1 mL 107 cells) was thawed from liquid
nitrogen in 378C water bath and quickly resuspended in
10 mL of fresh pre-warmed CD-CHO media. DMSO was
removed by 2000 g, 5 min centrifugation and resuspension
in 35 mL of pre-warmed media containing 250 mg/mL
Hygromycin B in a 125 mL cell flask. Three days of revival,
cells were passaged to 0.3 106 cell/mL into 150 mL of fresh
media in half litre bottom-baffled shake flasks. Flasks were
incubated at 378C 5% CO2 on an orbital shaker (125 rpm),
until they reached approximately 10 million cells/mL in
8 days. Viability was followed so that this did not drop
below 95%. On the day of harvest, cell broth from the flask
was transferred to 3 3 50 mL conical tubes and centrifuged
at 2000 g for 10 min to pellet the cells. The supernatant was
filtered through a 0.22 um stericup. Harvest Cell Culture Flu-
id (HCCF) was then concentrated 4-fold using multiple
10,000 MWCO (cat# 88527, ThermoFisher Scientific) cen-
trifugal concentrators (to approximately 30 mL).
Western blot for product detection
Proteins in clarified HCCF samples were fractionated by
SDS-PAGE and transferred to a PVFD membrane using an
XCell II Blot module according to the manufacturer’s proto-
cols (Invitrogen). After incubation with 5% non-fat milk in
PBST (Phosphate Buffered Saline Tween-20) for 60 min, the
membrane was washed once with PBST and incubated with
rabbit raised antibodies against GAA (1:1000) (cat.# ab137068
Abcam) at 48C for 12 h. Membrane was then washed three
times for 10 min in PBST and incubated with a 1:1000 dilu-
tion of horseradish peroxidase-conjugated anti-rabbit antibody
for 1 h at RT. Membrane was washed with PBST three times
and a diaminobenzidine detection kit (Sigma-Aldrich) was
used to highlight areas of GAA presence.
GAA purification first capture step: anion exchange
chromatography
A GE AKTA Avant 25 (GE Healthcare Life Sciences)
system was used to set up the anion exchange chromatogra-
phy capture step. The column used was a 1 mL GE CaptoQ
HiTrap and the buffers as follows; equilibration buffer
50 mM sodium acetate pH 6.0 (Buffer A), elution buffer
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1 M sodium chloride in 50 mM sodium acetate pH 6.0
(Buffer B) at a flowrate of 1 mL/min. Concentrated HCCF
was diluted 1:4 into equilibration buffer to adjust conductivi-
ty and favor binding of target material to resin. A 30 mL
volume was then loaded onto the column followed by a 14
CV wash (100% buffer A), 40 CV linear gradient elution (0-
35% buffer B), 5 CV strip (100% Buffer B) and regeneration
(10 CV 0.5 M NaOH, 5 CV Buffer A, 10 CV 20% EtOH).
2 mL fractions of column wash and eluate were collected
and absorbance at 280 nm monitored throughout the run.
The eluate was immediately frozen at 2208C until further
analysis.
The use of Zymograms to follow and identify protease
activity
NovexTM 12% Zymogram Casein Protein Gels (cat#
EC6405BOX Thermo Fisher Scientific) were used to visualize
protease presence pre- and post- capture step in null and GAA
CHO cells. Samples were first denatured in SDS buffer and
separated based on size similar to a standard SDS-PAGE gel,
then they were renatured by incubating the gel in non-ionic
detergents (renaturing buffer, Invitrogen) to re-establish enzy-
matic activity. The gel was then incubated overnight at RT in
developing buffer (Invitrogen) which adds divalent metal cati-
ons required for enzymatic activity. The following day the gel
was stained with Comassie blue and de-stained in 40% MeOH,
10% acetone. Regions of protease activity appear as clear
bands against a dark blue background where the protease has
digested the substrate.
HCP quantification via AlphaLISA
HCP content in HCCF and post capture chromatography
eluates was measured via Perkin Elmer AlphaLISA using a
commercially available CHO HCP (broad reactivity) Alpha-
LISA Detection Kit (cat# AL301C) read on an Envision
reader (Perkin Elmer) at 680 nm excitation/615 nm emission
following the manufacturers’ protocol.
HCP identification and quantification using high resolution
nanoLC-MS/MS
Eluate fractions post anion exchange from the three cell
lines (GAA Cell line1, null and mAb producing) were screened
via nanoLC tandem MS to determine HCP profile and presence
of product. LC-MS/MS analysis was undertaken by first digest-
ing samples with trypsin as described below, separating
digested peptides on UPLC and lastly injecting them into the
mass spectrometer. For digestion, post-AIEX column eluates
fractions were concentrated via 10000 MWCO concentrators
(Millipore) by a factor of 4. 50 mL of sample were mixed with
8 M urea in 100 mM NH4HCO31 1 mL 450 mM DTT. This
was allowed to incubate at RT for 1 h and followed by 15 min
incubation at RT with 10 mL 100 mM iodoacetamide. Final
protein concentration was determined with a NanoDrop instru-
ment at 280 nm. The urea concentration was then diluted with
64 mL of HPLC grade water. Digestion with trypsin was per-
formed for 1 h at 378C by adding to each sample 4 mg of
sequencing grade Trypsin (Promega V5111). A 2 mg/mL BSA
(Thermo Fisher) stock solution was used as a quantitation stan-
dard. 50 fmol of BSA was prepared by serial dilution and
spiked into each sample prior to separation to allow for label
free quantitation.
For peptide separation, 10 ll of sample was injected in
triplicate onto a HSS T3 Acquity column (Waters) 75 lm
internal diameter 3 15 cm (1.8 lm, 100 A) for on-line
reverse phase UPLC (Acquity M-Class, Waters). Elution was
performed with a linear gradient from 3 to 40% B over 40
min; (buffer A: 0.1% formic acid in water. Buffer B: 0.1%
formic acid in acetonitrile) at a flow rate of 300 nl/min. The
M-class mass spectrometer was coupled via a nanospray
source to a Synapt G2-Si (Waters) and data were collected
in HDMSe mode. Data were analyzed using Progenesis QIP
and searched against SwissProt using MSe Search with a
false detection rate of 4%. Progenesis QIP software provided
resulting data in the form of normalized average abundance
(molar equivalent) of each species matched in the SwissProt
database in triplicate readings. The average of each triplicate
was calculated eliminating eventual outliers. Average abun-
dances were converted to mass by multiplying them by the
respective molecular weights. Score and probability values
were used to avoid identification of false positives. In partic-
ular Anova (P) probability factor threshold was set at 0.1
max, which means that at P of 0.1, there is a 10% chance of
a false positive being identified.
Proteins identified were checked individually against the
UniProt database using accession IDs to determine biological
functions (proteolytic activity). Isoelectric point was calculat-
ed using ExPASy pI calculator online tool (ExPASy. Com-
pute pI/Mw tool). Hydropathicity index (GRAVY) was also
calculated based on amino acidic sequence. Relative percent-
age of each protein out of the total were also calculated and
used for the resulting bubble graph diagram.
Results and Discussion
Clonal CHO cell line generation
Generation of stable recombinant protein expressing mam-
malian cell lines was traditionally a long and tedious task,
mainly due to the bottleneck operation of clone selection, how-
ever with the advent of high throughout and cell sorting tech-
nologies this has become a much more stream lined procedure
such that stably expressing clones can typically be established
in 3-4 months.22 Transfection of a plasmid into a genome is a
rare random event and a very low number of clones, usually
1 in 10,00023 will present the desirable features of high titre
and good quality product. Due to this “location effect,”24 the
odds that a plasmid integrates in highly transcribed section of
the host genome (away from chromatin or other less transcribed
areas) are very low. It thus becomes necessary to screen thou-
sands of clones to select high producers.
In this work, we opted to use an alternative technique
based on site-directed recombination using Flp-In/FRT tech-
nology, which facilitates integration of the gene of interest
into a specific highly transcribed FRT site in the host
genome and allows all clones generated to produce consider-
able and comparable levels of recombinant product.25 Using
this technology, and the process outlined in the material and
methods section, three GAA producing cell lines were estab-
lished using LDC.
The three cell lines (GAA, mAb, and Null) were com-
pared in terms of growth performance (Figure 2A) and this
showed that the highest GAA producing cell line (#2) had
the slowest growth over a 6-day period, which may reflect
the impact of GAA expression on this cell line. Cell line 1
and 5 grew very similarly and reached viable cell numbers
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of 14 million per mL over the same 6 day period. Western
blot analysis of the HCCF (Figure 2B) confirmed the pres-
ence of the 106 KDa GAA isoform in all three cell lines as
well as in the pool sample (heterogeneous cell population
that emerged from stable transfection selection pressure
before applying LDC) and undetectable amounts of GAA in
an untransfected negative control (null). We also observed in
the same samples the presence of smaller GAA isoforms,
which could be the 70 and 76 KDa species described in the
literature.18 A GAA diagnostic assay that uses glycogen and
4-methylumbelliferyl-a-D-glucopyranoside as substrates for
measuring GAA activity and incorporates acarbose to elimi-
nate the interference of unrelated a-glucosidases21 was used
for quantification of GAA in HCCF samples (Figure 2C).
This assay showed a range of expression from approximately
0.05 to 0.25 mg/mL of GAA. These data are in accordance
with the western blot data. After having assessed these fac-
tors, cell line 1 was selected for further studies as it pro-
duced 0.18 g/l of GAA in harvest and was capable of
reaching 14 million cell/mL in 6 days.
Investigating the lysosomal phenotype with TEM in GAA
producing cells
After establishing that the GAA cell lines were expressing
the desired product, we next investigated any potential influ-
ence of this on the lysosomes of the recombinant cells com-
pared to the host. As explained in Figure 3, all mammalian
cells produce a basal amount of GAA, 10 to 20% of which
is secreted outside of the cell. The rest is transported to pre-
acidified compartments via mannose 6 phosphate binding
and is thus transported into the cells lysosomes. We wanted
to determine if GAA overexpression affected lysosomal mor-
phology by comparing images of lysosomes from the
recombinant GAA expressing cell line and the originating
null CHO cells. The resulting data are presented in Figure 3
and shows a clear difference in lysosomal phenotype
between null and GAA cells. While lysosomes are present in
similar numbers (about 18 per cell) and size (400 nm) in
both cell types, they are generally full and dark in recombi-
nant GAA and empty or mostly empty in null cells. Specifi-
cally, over 72% of lysosomes are completely full (F) in the
GAA cell line while only 8% present the same phenotype in
the null line. This trend was also observed when comparing
lysosomes containing some (%HF – half full) to no (%E -
empty) dark matter: only 17% of all lysosomes in the GAA
expressing cell line present this phenotype vs. 55% in null.
These data provide evidence that overexpression of GAA
leads to lysosomes becoming full and engorged. Potentially
this could contribute to the overall cellular stress levels
experienced by the cell.
Purification of recombinant GAA
To investigate how cell stress and HCP content in the cell
culture supernatant are linked to target protein overexpression,
we first designed an anion exchange step to capture GAA
from the clarified harvest feed. Previous attempts at alpha-
amylase purification involved anion-exchange chromatography
using mono-Q columns26 and affinity chromatography using
Concanavalin A Sepharose 4B for GAA.27 For this experi-
ment, we decided to use anion exchanger Capto-Q.
After growing the cell line in 100 mL CD-CHO, 8 mM
glutamine, HygromycinB containing media in cell flaks up
to 15 3 106 cells, the batch culture was harvested and partly
clarified via centrifugation. The GAA in the HCCF was then
partly purified via anion exchange capture step on an AKTA
Avant using CaptoQ resin. As can be seen in Figure 4A,
Figure 2. CHO GAA producing and control cell line comparison.
(A): cell growth performance; (B): product production via western blot; (C): product production quantification via GAA diagnostic assay.21 Although
cell line 2 was the highest producer, cell line 1 was the fastest grower. Cell line 1 was chosen due of good balance between growth and production
performance. Data show that null (N) cell line produces non detectable product as expected, and pool sample (P) secretes average level of GAA.
Pool sample is the sample used for cell line selection (all cell lines mixed). Medium used ThermoFisher scientific CD-CHO with 250 mg/mL HygB,
viability >93% at day 6 (null grown in same media without HygB).
Biotechnol. Prog., 2017, Vol. 00, No. 00 5
GAA eluted at a salt concentration range between 100 and
200 nM. Fractions were collected during flowthrough, elu-
tion and column strip and GAA presence was assessed via
western blot analysis. In Figure 4B, GAA was present in
varying concentrations only in the four elution fractions and
no GAA was observed in flowthrough and strip fractions.
The GAA bands were slightly below the expected molecular
weight for GAA (106 KDa as observed previously and in
MS data below), however so was the reference standard.
This can be attributed to the molecular weight standard
being compromised or inaccurate. The same fractions ana-
lyzed via SDS-PAGE (Figure 4C) further show the degree of
purification achieved by the ion exchange step. By compar-
ing the HCCF and IEX elution fractions (combined as illus-
trated), it is possible to visually observe the degree of HCP
removal by IEX. Target protein recovery was measured at
89% via the GAA diagnostic assay.
Protease characterization in material from the GAA and
null cell line using zymography analysis
Protease content in HCCF and elution fractions was com-
pared between the selected GAA cell line and its originating
null cell line to see whether overexpression of the target pro-
tein influences total protease activity and content. Initially, a
zymographic gel (Figure 5) gave a qualitative representation
of eluate protease content as it showed how the null eluate
contained more proteases than its GAA clonal counterpart
around the 80 KDa size. According to MS identification data
shown in the following results section (see also Supporting
Information – “HCP full list,” for complete HCP identifica-
tion), the only two proteases of 80 KDa size present in
both null and GAA IEX eluates are dipeptidyl peptidase 3, a
metalloproteinase, and prolyl endopeptidase, a serine pepti-
dase. The implications of the presence of these two proteases
coeluting with the product has not been evaluated. This
result called for further investigation, specifically identifica-
tion and quantification of those proteases present that might
impact on the quality of the final GAA product.
HCP characterization in a GAA expressing CHO cell line
compared to the null host and a monoclonal antibody
producing cell line as determined by high resolution
LC-MS/MS
In this experiment, we compared HCP content found in
capture step eluate fraction of three different CHO cell lines.
The GAA producing cell line 1, the null and the mAb produc-
ing were expanded and purified under the same conditions
and IEX eluate fractions were screened using high resolution
Figure 3. Transmission Electron Microscope images of null (A) and GAA (B) cells.
Cells were sampled at the same time from actively growing cultures, fixed and ultra-thin slices were prepared for TEM imaging (magnification
3000X). 33 images of single cells were taken per each sample. Lysosomes were counted and categorized based on content in Full (F), Half-Full
(HF) and Empty (E). Data were collated and analyzed in excel (black – null; gray – GAA). Images chosen are representative.
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nanoLC tandem mass spectrometry. The resulting data are
presented in Figure 6 and Table 1. The data are shown in Fig-
ure 6 as a bubble graph generated by plotting the 50 most
abundant species found in each cell line. These were ordered
by calculated pI (ExPASy Compute pI/Mw tool, SIB Swiss
Institute of Bioinformatics) on the X axis and by hydrophobic-
ity index GRAVY (ExPASy ProtoParam tool, SIB Swiss Insti-
tute of Bioinformatics) on the Y axis. Bubble size (diameter)
represents percent of a given protein out of the total mass and
was calculated by multiplying normalized abundance (aver-
aged among triplicate LC injections) by the protein molecular
weight. The relative quantification calculation of each protein
identified through this type of analysis is achieved via direct
comparison with the BSA reference standard spiked in the
samples before sample injection. In order for quantification to
be absolute there should be a reference standard per identified
ion or protein species, a clearly unfeasible solution. For this
reason, we are confident of HCP ID being correct, even
though the amounts of each protein are relative to the BSA
control.
As expected in cell line 1, GAA was the dominating spe-
cies in the IEX eluate accounting for over 36% of the total
by mass spectrometry. In the same GAA eluate sample, HCP
quantified via AlphaLISA (PerkinElmer, MA) accounted for
approximately 54% of total protein, in agreement with the
MS result above (data not shown). By comparison, GAA
accounted for approximately 2% by MS of the total species
found in null and mAb producing cell lines, further proof
that basal GAA levels are found across many mammalian
cells lines and that the GAA cell line is expressing recombi-
nant material. Actin, clusterin, drebrin, elongation factor 2,
and lysosomal protective protein (carboxypeptidase) are
some of the more common HCPs co-purifying due to their
Figure 4. Elution peak in AIEX chromatogram (A) is divided in four fractions and analyzed. Western blot analysis (B) shows absence
of GAA in flowthrough and strip, and its presence in the four elution fractions, with the main amount eluting in fraction 2
and 3 (prestained molecular weight standard cat# LC5925 Thermo Fisher). For SDS-PAGE SYPRO ruby (C) fractions were
combined (1–2 and 3–4). These data show presence of GAA at around 110KDa in both fractions together with lower molec-
ular species in minor quantity (ladder molecular weight standard cat# 26614 Thermo Fisher). Clarified Harvest (H) was
also run along for comparison.
Figure 5. Comassie blue stained casein Zymogram. From left:
null HCCF (null-H), null AIEX Eluate (null-E), Cell
line1 HCCF (C1-H), Cell line 1 AIEX Eluate (C1-E).
Protein samples are first separated according to molecular
weight via gel electrophoresis, then renatured and incubated
overnight in the gel containing casein substrate and finally
stained and de-stained. Areas that show proteolytic activity
appear as white bands over dark background. Data show that
AIEX is able to clear out the majority of proteases from HCCF
to Eluate sample except for some co-eluting ones at around 80
KDa. These were later putatively identified via MS as Dipep-
tidyl peptidase 3 and Prolyl endopeptidase. Furthermore,
amount of protease in GAA cell line 1 eluate seems to be less
than amount of proteases present in null eluate. Note: GAA, not
being a protease, is not visible in zymography.
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pI being within 1 unit of the target molecule. HCPs with
similar hydrophobicity to GAA but over 1 pI unit difference
were found to be passenger molecules that co-purified, some
most likely by “product-associated” interaction. This phe-
nomenon of co-purification with the product due to interac-
tion with the product itself (piggy backing), has been
described previously for antibodies.28,29 In this category, we
find: neuraminidase (pI 6.82), the protease involved in cleav-
ing glycosidic linkages in neuraminic acids; procollagen C-
endopeptidase enhancer 1 (pI 8.63) involved in cartilage and
bone formation; 40S ribosomal protein S6 (pI 10.83); the
kinase cAMP-dependent protein kinase catalytic subunit
gamma (pI 8.7); and dystroglycan (pI 9.4) a complex
involved in numerous processes such as cell survival and
migration and membrane assembly (source Uniprot.org).
In the antibody producing cell line IEX eluate, some of
the most abundant species found were antibody as
expected, accounting for about 25% of the total by MS. In
the pI range between 5 and 6, where direct adsorption to
the IEX resin is anticipated, other proteins found include:
legumain, a protease involved in lysosomal protein degra-
dation; thioredoxin a protein responsible for various redox
reactions through the reversible oxidation of its active cen-
ter, and proteases lysosomal protective protein and ferro-
chelatase. Outside the typical pI range for direct interaction
and therefore candidates for piggy-backing through the
Figure 6. High resolution LC-MS/MS. In blue target molecule GAA, in red HCPs with proteolytic activity, in grey all other HCPs.
Data show identification and quantification of HCP found in capture step (IEX) eluate fraction across the three cell lines (GAA cell line1, null and
mAb producing). Out of a total of 233 HCPs identified in the samples, 36 showed proteolytic activity. The first 50 more abundant species are
reported per each cell line and ordered by calculated pI (ExPASy Compute pI/Mw tool, SIB Swiss Institute of Bioinformatics) on the X axis and by
hydrophobicity index GRAVY (ExPASy ProtoParam tool, SIB Swiss Institute of Bioinformatics) on the Y axis. Bubble size represents percent of a
given protein out of the total mass and was calculated by multiplying normalized abundance (averaged among triplicate LC injections) by the protein
molecular weight. Post AIEX column eluate fractions were concentrated and digested with sequencing grade modified trypsin, 50 fmol of BSA stan-
dard was spiked in each digested sample before injection in LC to allow for label free quantitation. Separation via HSS T3 Acquity column (Waters)
75 lm internal diameter 3 15 cm (1.8 lm, 100A) on-line reverse phase UPLC (Acquity M-Class, Waters). Elution via linear gradient from 3 to
40% B over 40 min; (buffer A: 0.1% formic acid in water. Buffer B: 0.1% formic acid in acetonitrile), flow rate 300 nl/min. Separated peptides
were injected via nanospray source to a Synapt G2-Si (Waters), data collected in HDMSe mode. Data analyzed using Progenesis QIP and searched
against SwissProt using MSe Search and a false detection rate of 4%. Complete list of HCP identified in all samples is included in Supporting
Information – “HCP full list.”
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process are: CYR61 (pI 8.49), which promotes cell prolifer-
ation angiogenesis and cell adhesion; neuroaminidase (pI
6.8), dystroglycan (pI 9.4) and 40S ribosomal protein S6
(pI 10.8).
In the null profile range of HCPs with pI between 4.5 and
6.5, we observed clusterin, lysosomal protective protein, Com-
plement C3, thioredoxin (disulfide oxidoreductase), protocolla-
gen C-endopeptidase enhancer (peptidase), phosphoglycerate
mutase (kinase), lysosomal protective protein (serine carboxy-
peptidase), legumain (lysosomal hydrolysis), and the common
heat shock cognate protein 70 KDa.30 HCPs with pI> 6.5
were identified as dystroglycan (pI 9.4), 40S ribosomal protein
S6 (pI 10.8), matrix metalloproteinase-19 (pI 8.9). Interesting-
ly most of the HCPs identified in the pI> 6.5 range in this
sample, were common with those found in GAA and mAb
producer, a sign that their elution was not caused by product
associated interaction, as product in the null cell line is barely
present. We believe that they might interact with another
HCP that interacts with the resin.
Importantly, the cysteine protease cathepsin B and Z were
ubiquitously present in moderate quantity in all three cell
lines. More precisely cathepsin B was 0.60 lg/mL or 0.62%
of total protein content in GAA producer, 1.85 lg/mL or
0.83% of total protein in null and 0.04 lg/mL or 0.20% of
total protein in mAb producer. Cathepsin Z was 0.10 lg/mL
or 0.10% of total protein in GAA producer, 0.41 lg/mL or
0.18% of total protein in null and 0.01 lg/mL or 0.05% of
total protein in mAb producer. This suggests these are not
co-purifying with the products and are retained to some
extent by the resin, or, that they also co-purify with another
HCP that does interact with the resin. Such proteases may
present issues with the production of GAA.
With the exception of a small number of unique species
found in excess in the GAA line and reported in Table 1, the
HCP profile across the three cell lines was broadly similar
and in agreement with other studies.31 A list of the 50 most
abundant overlapping proteins common to all three cell lines
is found in Table 1. This overlap in HCPs across many dif-
ferent cell lines has been studied extensively in two recent
studies. In the first one,9 the authors compared HCPs in har-
vest supernatants of day 10, 12, and 14 cultures generated
by a null cell line and a recombinant IgG4-producing cell
line and reported that while there were increases in HCPs,
which they associated with viability decline later in culture,
there were many similarities between the cell lines and days
of harvest. In another study,32 the HCP profile of three dif-
ferent null cell lines was compared and it was reported that
despite differences in CHO lineage, upstream process, and
culture performance, the cell lines yielded similar HCP pro-
files. Furthermore, this study assessed that about 80% of the
most abundant 1000 proteins identified were common to all
three lines.
While the HCP profile in this study is largely similar
across the three cell lines, some HCPs are unique to the
GAA cell line. Table 1 (bottom) shows the relative distribu-
tion and calculated concentration of the four species that
were found to be particularly abundant in the GAA line and
almost absent in the other two. These are: (1) actin (cyto-
skeletal protein ubiquitously expressed in all eukaryotic
cells) where a relatively low amount was found in null and
mAbs lines, a much greater amount was found in GAA line
material; (2) drebrin (related to actin polymerization) which
was also present predominantly in the GAA cell line
material; (3) Probable dual-specificity RNA methyltransfer-
ase RlmN (involved in RNA formation); and (4) EGF-
containing fibulin-like extracellular matrix protein 1
(involved in cell adhesion and migration). We suspect that
this might be due to a combination of two factors: the large
amount of GAA in cell line 1 sample could possibly be
responsible for mass spectrometer detector sensitivity
Table 1. Overlapping and Unique HCPs
Name (lg/ml) GAA null Ab
Clusterin 3.5 7.6 0.2
Complement C3 3.4 13.5 0.6
Neuraminidase 2.8 0.1 1.6
Elongation factor 2 2.2 4.8 2.5




Pigment epithelium-derived factor 1.4 5.1 0.4
Procollagen C-endopeptidase enhancer 1 1.4 9.4 0.1
Heterogeneous nuclear ribonucleoprotein Q 1.2 3.2 0.2
Dystroglycan 1.0 6.1 0.2
Protein CYR61 1.0 1.6 0.7
Follistatin-related protein 1 0.8 2.9 0.2
Retinoid-inducible serine carboxypeptidase 0.8 1.4 0.2
Lysosomal protective protein 0.8 5.8 0.2
Importin-5 0.8 4.3 0.1
Nucleobindin-1 0.7 1.3 0.0
Dipeptidyl peptidase 3 0.7 2.6 0.1
Nucleobindin-2 0.6 1.6 0.0
Cathepsin B 0.6 1.8 0.0
78 kDa glucose-regulated protein 0.6 2.7 0.0
Nidogen-1 0.5 5.7 0.0
cAMP-dependent protein kinase catalytic
subunit gamma
0.5 4.7 0.0
Legumain 0.4 1.4 0.3
45 kDa calcium-binding protein 0.4 3.9 0.1
Actin-17 0.3 1.5 0.1
U2 small nuclear ribonucleoprotein A’ 0.3 1.2 0.1




Putative phospholipase B-like 2 0.2 1.2 0.0
40S ribosomal protein S6 0.2 3.7 0.1
Actin, gamma 0.2 1.4 0.1
Collagen alpha-l (VI) chain 0.2 0.9 0.0
Bone morphogenetic protein 1 0.2 0.9 0.1
Annexin A5 0.2 0.3 0.0
Rho GDP-dissociation inhibitor 1 0.2 2.3 0.0
Receptor-type tyrosine-protein phosphatase S 0.2 1.5 0.0
Nuclear migration protein nudC 0.2 0.3 0.0
Heat shock cognate 71 kDa protein 0.1 3.9 0.0
30S ribosomal protein S6 0.1 0.2 0.0
Heat shock 70 kDa protein 0.1 0.9 0.0
Small ubiquitin-related modifier 2 0.1 1.1 0.0
Chaperone protein dnaK2 0.1 2.4 0.0
Vitamin K-dependent protein S 0.1 0.6 0.0
POTE ankyrin domain family member E 0.1 0.0 0.0
Transmembrane protein 132A 0.1 0.8 0.0
Matrix metalloproteinase-19 0.1 1.3 0.0
Protein disulfide-isomerase 0.1 1.0 0.0
Cathepsin Z 0.1 0.4 0.0
Actin 7.7 0.0 0.0







List of the 50 most abundant overlapping HCP common to all three
cell lines (top) and four unique to GAA HCP (bottom). Values (calculat-
ed mg/mL) are ordered by abundance in GAA sample. HCP are consid-
ered “overlapping” when present in at least two out of three cell lines.
Concentration (mg/mL) is calculated by multiplying normalized abun-
dance value by molecular weight divided by sample volume (10 mL).
Normalized abundance value based on BSA reference standard
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saturation, which could explain quantification discrepancies
with the other two lines. This could also account for differ-
ences in the mAb cell line where a high concentration of
mAb is present. Also, the competitive behavior of different
species onto the anion exchange resin could have affected
the amount of target bound coeluting species.
Conclusions
In this work, we provide evidence that overexpression of a
lysosomal therapeutic recombinant protein impacts on the
lysosomal phenotype of a CHO cell line. We achieved this
by comparing cell lysosomal phenotype and HCP profile of
three CHO cell lines: a lysosomal biotherapeutic protein pro-
ducer (GAA), a mAb producer and a null. The analytical
approach based on lysosomal phenotype image analysis and
HCP screening using high resolution LC-MS/MS revealed
interesting results. Cell image analysis via TEM showed that
lysosomes of GAA producer cell line appear full and
engorged when compared to null cell line lysosomes. The
HCP profile of the three cell lines capture step eluate was
also compared using high resolution LC-MS/MS to see
whether HCP released during fermentation and harvest
would show any significant difference across the three cell
lines. As expected the majority of HCP are common to all
three cell lines, a phenomenon widely reported in litera-
ture9,31,32; however, the GAA producer showed large abun-
dance of four specific HCPs reported in the result section. At
present, we are unable to determine whether this result is
linked to GAA overexpression or alternatively could be due
to a combination of mass spectrometer detector saturation
which impaired quantitation of other species or also an effect
of the competitive binding behavior caused by the presence
of large amount of GAA in the feed of the GAA producer.
The cathepsin B and Z proteases believed to be responsible
for product degradation were found ubiquitously in all three
cell lines suggesting that they do not co-purifying with the
products but are likely retained to some extent by the resin,
or, that they co-purify with another HCP that does interact
with the resin. The data reported in this work provide a fur-
ther understanding of the nature and relative concentrations
of HCP impurities in biopharmaceutical samples and physi-
cal effects on the cell structure that target protein overex-
pression can have. These assays can be used as generic
methods for HCP analysis in the biopharmaceutical industry.
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